Patient preferences and experiences regarding thrombopoietin-receptor agonists for immune thrombocytopenia in the United Kingdom and Ireland (TRAPeze UK & IE study)

To establish the experiences with and preferences towards existing thrombopoietin-receptor agonist (TPO-RA) treatments of individuals with immune thrombocytopenia (ITP) in the UK and Ireland, based on treatment attributes. Responses from UK and Ireland individuals with ITP were collected in a pan-Eu...

Full description

Saved in:
Bibliographic Details
Published in:Hematology (Luxembourg) 2021-01, Vol.26 (1), p.799-808
Main Authors: McDonald, Vickie, Newland, Adrian, Morgan, Mervyn, Wilson, Koo, Nazir, Jameel, Maguire, Peter, Geldman, Emma, Wynne, Tammy
Format: Article
Language:English
Subjects:
Adult
discrete choice experiment
Female
Humans
Immune thrombocytopenia
Ireland - epidemiology
Male
Middle Aged
Patient Preference
Patient Satisfaction
Purpura, Thrombocytopenic, Idiopathic - drug therapy
Purpura, Thrombocytopenic, Idiopathic - epidemiology
real-world
Receptors, Thrombopoietin - agonists
thrombopoietin-receptor agonists
treatment preferences
United Kingdom - epidemiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To establish the experiences with and preferences towards existing thrombopoietin-receptor agonist (TPO-RA) treatments of individuals with immune thrombocytopenia (ITP) in the UK and Ireland, based on treatment attributes. Responses from UK and Ireland individuals with ITP were collected in a pan-European online survey (TRAPeze, [Thrombopoietin-Receptor Agonist Patient experience survey]) from 18 September 2020 to 18 February 2021. TRAPeze was a survey of treatment preference regarding TPO-RAs (using a discrete choice experiment design), participant demographics, disease characteristics, treatment history, overall satisfaction with therapy, direct healthcare resource utilization and wider social impact. The survey was completed by 32 UK respondents. Characteristics with the greatest influence on preference towards TPO-RA treatments were method of administration (odds ratio (OR) 5.6, 95% confidence interval (CI) 3.2-10.1) and drug-food interactions (OR 3.2, 95% CI 1.8-5.7). Particularly, participants were more likely to select an oral tablet over a subcutaneous injection (OR 7.4, 95% CI 3.6-15.1) and a treatment without food restrictions rather than with food restrictions (OR 3.6, 95% CI 1.8-6.8). This is the first study to quantify the preference of individuals with ITP towards TPO-RA treatment attributes and demonstrates preference for orally administered treatments, without drug-food interactions.
ISSN:1607-8454
1607-8454
DOI:10.1080/16078454.2021.1978689